Cochlear Corp.
This article was originally published in The Gray Sheet
Executive Summary
Introduces Nucleus 24 cochlear implant with 24 channels and ESPrit ear level speech processor for use in severe-to-profoundly deaf adults and profoundly deaf children over 18 months of age. Cochlear launched the Nucleus 22 channel cochlear implant in November 1985 for use in adults and later gained approval for pediatric use. Encased in a titanium shell, Nucleus 24 "offers the maximum number of stimulating electrodes in a cochlear implant," the firm maintains in a June 26 release. The implantable portion of the device requires one-third less space than prior implants and conforms to the shape of a very young child's head," the company notes, adding that over 2,000 people currently wear the device outside the U.S., where it debuted last year...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.